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Abstract
Background: How the immune microenvironment changes during neoadjuvant chemotherapy of primary breast
cancer is not well understood.
Methods: We analyzed pre- and post-treatment samples from 60 patients using the NanoString PanCancer IO360™
assay to measure the expression of 750 immune-related genes corresponding to 14 immune cell types and various
immune functions, and assessed TIL counts and PD-L1 protein expression by immunohistochemistry. Treatment
associated changes in gene expression levels were compared using t-test with Bonferroni correction. TIL count, PD-
L1 protein and immune metagenes were compared using Wilcoxon test. Baseline immune markers were correlated
with pathologic complete response (pCR) using estrogen receptor and treatment arm adjusted logistic regression.
Results: At baseline, high TIL counts and high expression of chemoattractant cytokines (CCL21, CCL19) and cytotoxic T
cell markers were associated with higher pCR rate. High expression of stromal genes (VEGFB, TGFB3, PDGFB, FGFR1,
IGFR1), mast and myeloid inflammatory cell metagenes, stem cell related genes (CD90, WNT11, CTNNB1) and CX3CR1,
and IL11RA were associated with residual disease (RD). After treatment, in cases with pCR, TIL counts and most immune
genes decreased significantly. Among RD cases, TIL counts and PD-L1 expression did not change but cellular stress and
hypoxia associated genes (DUSP1, EGR1), and IL6, CD36, CXCL2, CD69 and the IL8/VEGF metagene increased.
Conclusions: Activated T cells in the tumor microenvironment are associated with pCR whereas stromal functions are
associated with residual disease. Most immune functions decrease during neoadjuvant chemotherapy but several
immunotherapy targets (PD-L1, IL6, IL8) remain expressed in RD suggesting potential therapeutic strategies.
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Background
Immune cells in the microenvironment of breast cancer
influence, and may partially mediate, response to chemo-
therapy [1–3]. Pre-operative (neoadjuvant) chemother-
apy of newly diagnosed, early stage breast cancer where
pre- and post-treatment tissues are available provides an
opportunity to study baseline immune parameters that
are associated with treatment response and to assess
changes in the immune microenvironment caused by
treatment. Several studies have reported that the higher
the tumor infiltrating lymphocyte (TIL) count, or
immune-related gene expression at baseline, the greater
the probability of pathologic complete response (pCR) to
preoperative chemotherapy in all breast cancer subtypes
[3–6]. However, the contribution of various lymphocyte
and immune cell sub-types to determining treatment re-
sponse remains unknown. To date, few studies examined
immunological changes in the breast tumor microenvir-
onment after chemotherapy [7, 8]. Better understanding
of the immune functions that influence the probability
of pathologic complete response (pCR) to preoperative
chemotherapy could suggest novel immunotherapeutic
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strategies to enhance chemotherapy efficacy. Patients with
extensive residual invasive cancer in the breast or lymph
nodes after preoperative chemotherapy have guarded
prognosis, particularly if they have triple negative breast
cancer [9]. Better understanding of the immune milieu of
residual cancers may also suggest novel therapeutic ap-
proaches to improve the prognosis of these patients.
S0800 (NCT00856492) was a randomized, 3-arm, Phase
II trial that tested if inclusion of bevacizumab with neoad-
juvant chemotherapy could improve pCR rates in
HER2-negative, locally advanced, or inflammatory breast
cancer (IBC). The three arms of the trial were weekly
nab-paclitaxel and bevacizumab followed by dose-dense
doxorubicin/cyclophosphamide (ddAC) (Arm A),
nab-paclitaxel followed by ddAC, (Arm B), and ddAC
followed by nab-paclitaxel (Arm C). Patients were ran-
domly allocated in 2:1:1 ratio to arms A, B and C, respect-
ively. For the primary efficacy analysis, the arms B and C
were combined. The trial demonstrated that bevacizumab
increased pCR rate from 21 to 36% (p = 0.019) but chemo-
therapy sequence in the non-bevacizumab arms did not
significantly influence efficacy [10]. The main objectives of
the current study were to (i) examine the association be-
tween pCR and pre-treatment TIL count, PD-L1 protein
expression and expression of 750 immune-related genes
and (ii) assess changes in these immune parameters in
paired pre- and post-treatment tissues.
Methods
Patients and samples
Of the 215 patients accrued to the S0800 trial, 134 patients
had pre-treatment and 63 patients had post-treatment
formalin fixed paraffin embedded (FFPE) tissues with con-
sent for research, including 60 patients with paired tissues
(Additional file 1: Figure S1). Pathologic complete response
was determined by the local pathologists and was defined
as the absence of any residual invasive cancer in the breast
and axilla (pCR = ypT0/is, ypN0). Patients who had any vi-
able residual cancer after chemotherapy, regardless of clin-
ical response, were categorized as residual disease (RD).
The current biomarker analysis was approved by the NCI
and the Yale Cancer Center Human Investigations Com-
mittee. Demographic and disease characteristics for the
overall trail and current immune marker study populations
are shown in Table 1.
TIL assessment
TILs counts were determined by a pathologist (V.P.) on
hematoxylin eosin stained full sections following the scor-
ing guidelines of the International Immuno-Oncology Bio-
marker Working Group on Breast Cancer [11]. Stromal
TIL scores were defined as the percentage of tumor
stroma area that was occupied by mononuclear inflamma-
tory cells. Inflammatory infiltrates in the stroma of nonin-
vasive lesions and normal breast structures were excluded
from TIL counts. In cases with pCR, the original tumor
bed was examined and scored.
PD-L1 immunohistochemistry
PD-L1 immunohistochemistry (IHC) was performed on
5 μm FFPE whole tissue sections using the FDA cleared
22C3 assay on the Dako Link 48 staining platform fol-
lowing the manufacturer’s instructions [8]. For controls,
we used slides from the DAKO 22c3 pharmDx assay that
Table 1 Demographic and disease characteristics for the overall trial population and the immune-related gene expression subset.
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includes a PD-L1 positive (NCI-H226) and a PD-L1 nega-
tive (MCF-7) cell line. Staining in tumor and stromal cell
compartments were scored separately as a percentage of
cells with PD-L1 signal of any intensity. PD-L1 positivity
was defined as > 1% of tumor or stromal cells staining
positive. This threshold was used in metastatic breast can-
cer trials for patient selection for anti-PD-1 therapy with
pembrolizumab and atezolizumab [12].
Transcriptional profiling
Total RNA was isolated from 5 μm FFPE sections using the
Qiagen RNeasy FFPE kit and 100 ng RNA was hybridized
to the beta version of the NanoString PanCancer IO 360
code set and read on the nCounter platform (NanoString).
The expression 750 immune-related genes and 20 house-
keeping genes were assessed. The nSolver 2.6 software was
used to normalize expression values using housekeeping
genes following the manufacturer’s recommendations [13].
Twenty of the 120 samples were excluded from further
analysis due to low geometric mean of housekeeper gene
expression. The remaining 100 samples from 57 patients
included 43 pairs of matched pre- and post-treatment sam-
ples. Genes were grouped into 14 immune cell type meta-
genes (total T, Th1, Treg, Total CD8, exhausted CD8,
Cytotoxic T, B, NK, NK-CD56, Mastoid cell, CD45, Den-
dritic cell, macrophage, neutrophil) and 39 immune func-
tions according to the manufacturer’s designation
(Additional file 2: Table S1). The metagene scores were cal-
culated as the geometric mean expression of the member
genes [14]. We also examined 26 previously published
prognostic and immune therapy response predictive meta-
genes (Additional file 3: Table S2). We calculated these
metagene scores following the methods described in the re-
spective publications. Normalized gene expression data is
deposited in the Gene Expression Omnibus database
(GSE114403).
Statistical analysis
All immune marker data was generated without know-
ledge of the patient outcomes. TIL counts and PD-L1
expression levels were compared between the pCR and
RD groups using the Wilcoxon rank-sum test and be-
tween the pre- and post-treatment samples using the
paired Wilcoxon test. Baseline immune gene mRNA ex-
pression was correlated with pCR using estrogen recep-
tor (ER) and treatment arm adjusted logistic regression.
Treatment associated changes in gene expression levels
were compared using t-test with Bonferroni correction.
Results
TIL counts
At baseline, cases with pCR had significantly higher TIL
counts than cases with RD (p = 0.0129, Fig. 1a). TIL
counts remained significantly associated with pCR (p =
0.0243), after adjustment for ER status and treatment arm.
Among patients with pCR, TIL counts were signifi-
cantly lower in post-treatment samples compared to
pre-treatment (p = 0.00063, Fig. 1b). Among RD cases,
there was no significant difference in pre- and
post-treatment TIL counts (p = 0.1263, Fig. 1c). How-
ever, a substantial subset of cases had numerically de-
creased post-treatment TIL count (n = 20) while a in a
few cases TIL count increased (n = 8), but there was no
difference in disease-free or overall survival by decrease
or increase in TIL count in the residual cancer.
PD-L1 protein expression in tumor and stromal cells
Tumor cell PD-L1 protein expression did not change
significantly after treatment, in either response group
(Fig. 2a, b) and there was no association between base-
line PD-L1 expression and response to therapy (Fig. 2c).
Stromal PD-L1 expression was also similar between pre-
and post-treatment samples (Fig. 2d, e) and between re-
sponse groups (Fig. 2f ).
We also compared PD-L1 expression by immunohisto-
chemistry and by mRNA measurements. Samples show-
ing positive PD-L1 protein expression, in either stromal
or cancer cells, had significantly higher PD-L1 (CD274)
mRNA expressions than samples showing no PD-L1
protein expression (Fig. 3).
PD-L1 percent positivity either on tumor (r2 = 0.23, p
= 0.04) or stromal cells (r2 = 0.38, p = 0.0003) correlated
weakly but significantly with TIL percent count
(Additional file 4: Figure S4 A, B). PD-L1 positive cases,
either on tumor or stromal cells, also showed signifi-
cantly higher TIL counts compared to PD-L1 IHC nega-
tive cancers (Additional file 4: Figure S4 C, D).
Baseline immune gene expression and response to
therapy
In ER status and treatment arm adjusted logistic regression
analysis, higher expression of 24 immune genes were sig-
nificantly associated with pCR (Fig. 4a). These included sev-
eral activated cytotoxic T cell markers such as granzyme,
granulysin, CD7 and chemoattractant cytokines CCL21 and
CCL19. Expression of IL7R, that promote V(D)J T cell re-
ceptor and immunoglobulin recombination during lympho-
cyte maturation was also higher in cases with pCR.
A different and substantially larger number of immune
genes (n = 63) were significantly associated with RD
(Fig. 4a). Many of these genes were related to fibroblast
and stromal functions (COL4A5, COL5A1, COL6A3,
COL10A1, TIMP3, CDH-2, − 11, − 13, CHAD, VACN),
some representing therapeutic targets including VEGFB,
TGFB3, PDGFB/PDGFRB, FGFR1 and IGF1R. VEGF
expression was not associated with response to bevacizu-
mab in this study. The low affinity Fc gamma receptor
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(FCGR2A/CD32), the cytokine receptor CX3CR1 and
IL11RA were also higher in cancers with RD. CXCR1 and
IL11R represent potential therapeutic targets since they
promote macrophage survival and induce apoptosis resist-
ance in cancer cells [14] and also stimulate cancer cell
survival and promote angiogenesis and metastasis forma-
tion [15], respectively. High expression of the putative
cancer and hematopoietic stem cell marker THY1/CD90
and WNT11 and CTNNB1 also suggest potential novel
therapeutic strategies to increase pCR rates.
A B C
Fig. 1 Tumor infiltrating lymphocyte (TIL) counts in cases with pathologic complete response (pCR) and residual disease (RD), and in pre- and
post-treatment samples. a Box plots of baseline TIL counts in cases with pCR and RD. Triangles and dots/circles represent patients in the
bevacizumab and control arms, respectively. Open and dark symbols indicate estrogen receptor positive and negative patients, respectively. b
Changes in TIL counts in the tumor bed of cases with pCR. c Changes in TIL counts in cases with RD. Paired pre- and post-treatment samples are
connected by lines to indicate up or down change in each individual. P values are from Wilcoxon test
A B C
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Fig. 2 PD-L1 protein expression in cases with pathologic complete response (pCR) and residual disease (RD), and in pre- and post-treatment
samples. a PD-L1 expression changes on tumor cells in cases with pCR (Wilcoxon test p = 0.435). b PD-L1 expression changes on tumor cells in
cases with RD (Wilcoxon test p = 0.502). Pre- and post-treatment samples from the same patient are connected with lines. c PD-L1 expression
comparisons between pCR and RD cases for all baseline samples (Wilcoxon test p = 0.1578). Shape and color of each dot represent treatment arm
and ER status. d-f Similar figures as a-c showing changes and PD-L1 changes in stromal cells. Symbols ae the same as on Fig. 1
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A B
Fig. 3 PD-L1 protein and mRNA expression. a PD-L1 mRNA levels in cases with positive and negative PD-L1expression on tumor cells. b PD-L1




Fig. 4 Immune genes associated with response and immune gene expression changes after treatment in cases with pathologic complete
response (pCR) and residual disease (RD), respectively. a Volcano plots of the log odds ratio of gene expression by pathologic response status.
Each dot represents a gene, the x-axis shows the log2-transformed correlation coefficient for response. Positive values indicate higher expression
in the pCR cohort, negative values indicate higher expression in the RD cohort. The y-axis shows -log10-transformed p-values from logistic
regression, genes with p < 0.05 are colored red and annotated with names. b Volcano plot of gene expression changes in pre- and post-
treatment pCR samples. c Volcano plot of gene expression changes in pre- and post-treatment RD samples. On panels B and C, the x-axis shows
the log2-transformed expression difference between pre- and post-treatment tissues; positive values indicate higher expression in post-, and
negative values indicate higher expression in pre-treatment samples. The y-axis shows -log10-transformed p-values. Genes that remained
significant after Bonferroni adjustment (adjusted p < 0.05) are in red
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At the metagene level, most immune cell types and
immune functions showed similar or higher baseline ex-
pression in cases with pCR compared to RD except a
mast cell signature and stroma and myeloid inflamma-
tory cell signatures that were higher in patients with RD
(Fig. 5a, b). None of the 26 previously reported prognos-
tic or immunotherapy predictive signatures showed sig-
nificant association with pCR after adjustment for ER
status and treatment arm.
Age was not predictive of pCR in this study
(Additional file 5: Figure S2A). MKI67 (Ki67) mRNA ex-
pression levels were also similar between cases with RD and
pCR at baseline (p= 0.107, Additional file 5: Figure S2B) and
in the post-treatment samples (p= 0.2823, Additional file 5:
Figure S2C). Because most cases were stage III invasive
ductal carcinomas (N= 2 inflammatory breast cancer), we
could not correlate clinical stage or histology with pCR.
Changes in immune gene expression after chemotherapy
At the individual gene level, most immune genes had
lower expression in post-treatment samples in both re-
sponse groups. However, in cases with pCR, cellular
stress and hypoxia associated genes (DUSP1, EGR1,
CPA3, GAS1) and TNFSF12 showed increased expres-
sion post-treatment (Fig. 4b). In cases with RD, DUSP1
and EGR1 also showed increased expression
post-treatment as well as IL6, ATF3, CD36, CXCL2,
CD69, NGFR, KLF2, THBD, DAB2 and C7 (Fig. 4c).
These genes are involved with tissue repair and inflam-
mation after injury. Among known therapeutic targets in
clinical development, CTLA4, PD-L1 and IDO1 expres-
sion remained unchanged in residual tissues.
At the metagene level, in both response cohorts, all im-
mune cell metagene expressions decreased, except the NK
cell metagene that remained the same. The mast cell meta-
gene increased in post-treatment tissues of patients with
pCR (Fig. 5c, d). Metagenes representing immune-related
functions also decreased in the post-treatment tissues in
both response groups except IL10 signaling, NOS2, ARG1
and APM and MMR loss that remained unchanged in both
response cohorts (Fig. 5e, f).
We also examined the expression of 26 previously
published prognostic and immunotherapy response pre-
dictive immune gene signatures. Most of these showed
lower expression in post-treatment samples in both re-
sponse groups (Fig. 6a, b). The decrease was statistically
significant for the Interferon, MHC1, STAT1 and Treg
signatures in both cohorts. Only the IL8/VEGF gene
signature showed significantly higher expression in
post-treatment samples in both response groups in (pCR
A B
C D E F
Fig. 5 Expression of immune metagenes in cases with pathologic complete response (pCR) and residual disease (RD) and in pre- and post-
treatment samples. a Expression of immune cell type metagenes in cases with pCR and RD. b Expression of immune function metagenes in cases
with pCR and RD. c Expression of immune cell type metagenes in pre- and post-treatment samples, in cases with pCR. d Expression of immune
cell type metagenes in pre- and post-treatment samples, in cases with RD. e Expression of immune function metagenes in pre- and post-
treatment samples in cases with pCR. f Expression of immune function metagenes in pre- and post-treatment samples in cases with RD
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cohort: p = 0.038, in RD cohort: p = 0.017). The
activated-CD4 gene signature also showed significantly
higher expression in post-treatment samples of patients
with RD (p = 0.026).
We have also compared the IL8/VEGF immune gene
signature and TIL counts between the treatment arms with
or without bevacizumab and found that the IL8/VEGF
signature showed significantly higher expression in post-
treatment samples in both treatment arms whereas TIL
counts were significantly lower in post-treatment samples
in both treatment arms (Additional file 6: Figure S3). No
treatment-arm specific changes could be detected.
Discussion
In this study, we examined associations between baseline
immune markers and response to nab-paclitaxel and
doxorubicin/cyclophosphamide neoadjuvant chemother-
apy with or without bevacizumab and assessed changes
in the tumor immune microenvironment after treat-
ment. We confirmed earlier observations that higher
baseline TIL counts are significantly associated with
higher pCR rate even after adjustment for ER and treat-
ment arm [4, 13]. We also identified several immuno-
logical functions that provide additional granularity to
this association. The significantly higher baseline expres-
sion of granzyme and granulysin in the tumor micro-
environment of patients who subsequently experience
pCR are consistent with the preclinical models that indi-
cate synergy between cytotoxic T cell activity and the an-
titumor effect of chemotherapy [2, 3]. The high
expression of CCL19 and CCL21 in TIL-rich cancers
suggests that these chemokines play important roles in
attracting T cells, NK cells and mature dendritic cells
into the tumor tissues. This raises the possibility
re-activation, or supplementation, of these cytokines in
immune-poor cancers may turn “immune cold” cancers
into “immune hot” tumors. The high baseline expression
STAT4, CD7 and IL7R in cases with pCR also suggest
that T helper activity and T and B cell maturation are
important for achieving pCR whereas the high expres-
sion of IL1RN (Interleukin-1 Receptor Antagonist), that
suppresses IL1 signaling, suggests that IL-1 activity con-
fers chemotherapy resistance. We were not able to iden-
tify any single gene or immune metagene that was
selectively predictive of greater sensitivity to bevacizu-
mab. VEGF expression and angiogenesis signatures, had
no statistically significant interaction with bevacizumab
effect. However, due to the small samples size, the power
of this study to detect such interaction is small.
Perhaps more importantly, we also identified a larger
number of stroma-related functions and immune parame-
ters that were negatively associated with pCR in all treat-
ment arms. Baseline expressions of mast (MS4A2, CPA3,
HDC, TPSB2) and myeloid inflammatory cell metagenes
(CXCL1, CXCL3, CXCL2, CCL20, AREG, FOSL1, PTGS2,
IER3, IL6) were higher in patients with RD. This raises the
possibility that mast cell inhibitors (e.g. masitinib) or IL6
antagonists (e.g. tocilizumab) might convert some patients
from RD to pCR. Inhibition of CXCL1, CXCL3, CXCL2,
and CCL20 may also increase chemotherapy efficacy. We
also noted high baseline expression of several other poten-
tial therapeutic targets including VEGFB, TGFB3,
PDGFB/PDGFRB, FGFR1 and IGF1R in cancers that did
not achieve pCR. The concurrent administration of the
anti-VEGF antibody bevacizumab with chemotherapy has
increased pCR rates in this and several other randomized
A B
Fig. 6 Change in immune metagene and immunotherapy response predictive gene signatures before and after treatment in the two response
groups. a. Immune gene signature expression changes in pre- and post-treatment samples from pCR cases, represented by odds-ratio and its
95% confidence interval from logistic regression. b. Immune gene signature expression changes in pre- and post-treatment samples from RD
cases, represented by odds-ratio and its 95% confidence interval from logistic regression. * indicate a trend with 0.05 < p < 0.1 and ** indicate
significance with p < 0.05
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neoadjuvant trials (ARTemis, CALGB-40603, SWOG-
S0800, NSABP-B40 GeparQuinto), indicating that inhib-
ition of the VEGF axis increases chemotherapy sensitivity.
However, two large adjuvant trials (BEATRICE,
ECOG-5103) have not shown increased disease-free or
overall survival with the inclusion of bevacizumab [16].
When we compared immune parameters in pre- and
post-treatment tissues, we noted an almost universal reso-
lution of the immune and inflammatory response in cases
with pCR. We previously reported in a larger number of
samples from the same study (124 pre- and 62
post-treatment tissues) that TIL counts generally decrease
in post-treatment tissues [8]. These observations suggest
that either chemotherapy has a cytotoxic effect on TILs or
as the size of the primary tumor decreases in response to
therapy, the immunogenic target decreases and the corre-
sponding anti-tumor immune reaction also winds down.
The greatest decrease in TILs between matched pre−/post--
treatment samples is observed in cases with pCR that sup-
ports the hypothesis that after complete eradication of the
cancer from the breast the immune response also resolves.
Indeed, among RD cases, there was no significant difference
in pre- and post-treatment TIL counts. However, most im-
mune cell metagene expressions decreased significantly even
among cases with RD, except the NK cell metagene that
remained the same, and the mast cell metagene that has in-
creased, in post-treatment tissues. The few genes that
showed increased expression in residual tissues after pCR
included cellular stress and hypoxia induced genes suggest-
ing ongoing tissue repair. In cases with RD, we observed in-
creased expression of a larger number of genes in the
residual tissues including several of the same stress- and
hypoxia-induced genes (DUSP1, EGR1) as in pCR. The Dual
Specificity Phosphatase 1 (DUSP1), is of interest since in
some solid tumors it can induce resistance to both chemo-
therapy and radiotherapy in vitro and in vivo [17]. In
addition, we also observed increased expression of IL6 and
CXCL2 in RD tissues. Both cytokines were also associated
with RD at baseline and represent attractive
immuno-oncology targets to enhance chemotherapy effi-
cacy. Several studies implicated high levels of IL6 in poor
prognosis and lesser treatment response in breast cancer
[18]. The chemokine ligands CXCL-1 and -2 were also
shown to promote breast cancer metastasis through myeloid
cell recruitment and blocking CXCL-1 and -2 signaling im-
proves chemotherapy efficacy in experimental models [19].
There are a few limitations of this study. Our small sam-
ple size prevented us from adequately powered analysis by
ER groups, which possess different immunologic character-
istics and chemotherapy sensitivities. Several other poten-
tially important subset analyses that we have performed
have limited power. We observed no significant difference
in survival among residual disease cases that showed in-
crease in TIL count from baseline compared to those that
had a decline, we also failed to detect significant associ-
ation between baseline PD-L1 expression and pCR, as we
reported earlier in larger cohorts [5, 8]; these findings
most likely reflect underpowered analyses. We also
recognize that our pre- and post-treatment sample com-
parisons may be influenced by unavoidable sampling bias
and treatment-related shifts in tumor cellularity. All base-
line tissues were from core needle biopsies and all
post-treatment samples were from surgically resected tis-
sues and post-treatment samples generally have lower
tumor cellularity even in cases with residual disease.
Conclusions
Our analysis suggests that CCL19, CCL21 and IL7 sig-
naling play an important role in attracting and activating
immune cells in the breast cancer microenvironment
and might help convert immune cold cancers to im-
mune hot. The presence of activated cytotoxic T cells
with granzyme and granulysin expression are important
for achieving pCR with chemotherapy. The expression of
CXCL1, CXCL3, CXCL2, CCL20, and IL6 are enriched
in residual cancer and are associated with lesser re-
sponse the chemotherapy when highly expressed at
baseline. These molecules represent potential novel tar-
gets to increase pCR rates and improve outcome in pa-
tients with residual cancer after chemotherapy.
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